GlassScriptPhysician profile
Amy Alston
NPI 1013528629
$3,650.20
in general payments reported to CMS, 2019-2025
29 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $373 · 2024: $786 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.98 |
| Education | $455.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $724.69 | 2024-2025 | |
| Astellas Pharma US INC | $358.59 | 2023-2024 | Veozah |
| Janssen Biotech, INC. | $250.24 | 2024-2025 | Tremfya, Stelara, Simponi |
| Incyte Corporation | $247.33 | 2024-2025 | Opzelura, Opzelura |
| Organon LLC | $226.78 | 2023-2025 | Vtama, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $225.20 | 2024-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $182.03 | 2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $166.99 | 2024-2025 | |
| Galderma Laboratories, L.P. | $166.87 | 2025 | Nemluvio, Aklief |
| Ucb, INC. | $157.42 | 2024-2025 | Bimzelx |
| Kerecis Limited | $122.32 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $121.66 | 2024-2025 | Sotyktu |
| Abbvie INC. | $111.92 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $84.51 | 2022 | |
| Amgen INC. | $72.73 | 2024-2025 | Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $64.55 | 2025 | Zelsuvmi |
| Sun Pharmaceutical Industries INC. | $61.95 | 2024-2025 | |
| Medimetriks Pharmaceuticals, INC. | $57.20 | 2024-2025 | Clindacin Etz, Neo-Synalar |
| Pfizer INC. | $33.81 | 2023-2025 | |
| Almirall LLC | $31.50 | 2025 | Klisyri |
| Novartis Pharmaceuticals Corporation | $27.32 | 2025 | |
| Arcutis Biotherapeutics, INC. | $24.92 | 2025 | Zoryve |
| Journey Medical Corporation | $24.56 | 2025 | |
| Organogenesis INC. | $22.98 | 2025 | Novachor |
| Mayne Pharma Commercial LLC | $18.92 | 2025 | |
| Therapeuticsmd, INC. | $17.14 | 2022 | |
| Lilly USA, LLC | $16.55 | 2024 | Ebglyss |
| Biofrontera INC. | $15.30 | 2025 | |
| Verrica Pharmaceuticals INC. | $14.22 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Alston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.